SCHEMBL17545178

SCHEMBL17545178

FC(F)(F)c1cnc(Nc2cccc3ccccc23)nc1Nc1cccc2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 5/20 1.00
CDC7 O00311 1/20 0.54
ROCK2 O75116 1/20 0.54
MAP4K4 O95819 1/20 0.54
PIM1 P11309 1/20 0.54
PRKACA P17612 1/20 0.54
CDK7 P50613 1/20 0.54
CDK9 P50750 1/20 0.54
HIPK2 Q9H2X6 1/20 0.54
IRAK4 Q9NWZ3 1/20 0.54
SYK P43405 1/20 0.52
AURKA O14965 1/20 0.50
GSK3A P49840 1/20 0.49
GSK3B P49841 1/20 0.49
PTK2 Q05397 2/20 0.48
MAPK3 P27361 5/20 0.48
CDK1 P06493 1/20 0.47
CDK4 P11802 1/20 0.47
CDK2 P24941 1/20 0.47
KDR P35968 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29575321 1.00 ULK1 (1.00) ULK1CDC7ROCK2MAP4K4PIM1
SCHEMBL1917484 0.82 ULK1 (0.70) ULK1MAPK3
SCHEMBL1917489 0.82 ULK1 (0.70) ULK1MAPK3
SCHEMBL29575332 0.80 ULK1 (0.66) ULK1CDC7ROCK2MAP4K4PIM1
SCHEMBL17547451 0.80 ULK1 (0.66) ULK1CDC7ROCK2MAP4K4PIM1
SCHEMBL19654290 0.78 ULK1 (0.64) ULK1SYKAURKAMAPK3KDR
SCHEMBL17544782 0.77 ULK1 (1.00) ULK1CDK7PTK2CDK1PTK2B
SCHEMBL17547513 0.76 ULK1 (1.00) ULK1CDC7ROCK2MAP4K4PIM1
SCHEMBL29574731 0.76 ULK1 (1.00) ULK1CDC7ROCK2MAP4K4PIM1
SCHEMBL12998612 0.76 PTK2 (0.77) ULK1CDK7PTK2CDK1PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 2023-04-27 US disclosed
WO-2021163633-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 WO disclosed
US-10774092-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-09-15 US disclosed
US-10689397-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2020-06-23 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-08-15 US disclosed
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-05-23 US disclosed
US-10266549-B2 ULK1 inhibitors and methods using same SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2019-04-23 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-11-30 US disclosed
EP-3185868-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME Salk Institute for Biological Studies (US) 2017-07-05 EP disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed
WO-2016033100-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10689397-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885CDC7 135/4885ROCK2 1906/4885
US-10266549-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885CDC7 135/4885ROCK2 1906/4885
US-20230130766-A1 MONO AND COMBINATION THERAPIES WITH ULK1/2 INHIBITORS ULK1, ULK2, ULK3 ULK1 1/4885CDC7 52/4885ROCK2 1837/4885
US-20170342088-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885CDC7 174/4885ROCK2 2140/4885
US-20190248806-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885CDC7 174/4885ROCK2 2140/4885
US-20190152989-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885CDC7 174/4885ROCK2 2140/4885
US-10774092-B2 ULK1 inhibitors and methods using same ULK1, ULK2, ULK3 ULK1 1/4885CDC7 135/4885ROCK2 1906/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 ULK1 1/4885CDC7 174/4885ROCK2 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.